aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in Cambridge, United States, Ribon Therapeutics is a clinical-stage biotechnology company focused on pioneering the development of first-in-class small molecule inhibitors. Their core mission is to discover and develop novel therapeutics that target cellular stress pathways, specifically aimed at blocking the survival mechanisms of cancer cells. Ribon's product pipeline includes inhibitors like RBN-2397, a PARP7 inhibitor, and RBN-3143, a PARP14 inhibitor, which are designed to disrupt NAD+-utilizing enzymes critical for cancer cell survival.
Ribon Therapeutics is backed by a distinguished team of scientific advisors and a robust board of directors, with significant investments from leading venture capital firms. The company has achieved key milestones, including advancing its lead compounds into clinical trials and publishing influential scientific research. Ribon's innovative approach has the potential to significantly impact cancer treatment by targeting the fundamental stress support pathways that cancer cells rely on, offering new hope for patients with hard-to-treat cancers.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Cancer Therapeutics
Technology
Biotech
Tags
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Ribon Therapeutics founded?
Ribon Therapeutics was founded in 2015.
Where is Ribon Therapeutics's headquarters located?
Ribon Therapeutics's headquarters is located in Cambridge, MA, US.
When was Ribon Therapeutics's last funding round?
Ribon Therapeutics's most recent funding round was for $25M (USD) in December 2022.
How many employees does Ribon Therapeutics have?
Ribon Therapeutics has 57 employees as of Feb 5, 2024.
How much has Ribon Therapeutics raised to-date?
As of July 05, 2023, Ribon Therapeutics has raised a total of $259M (USD) since Dec 22, 2022.
Add Comparison
Total Raised to Date
$259M
USD
Last Update Dec 22, 2022
Last Deal Details
$25M
USD
Dec 22, 2022
Series Unknown
Total Employees Over Time
57
As of Feb 2024
Ribon Therapeutics Address
35 Cambridgepark Drive
Cambridge,
Massachusetts
02140
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts